



Supplemental Figure S4. Sensitivity of OCI-AML2 CRISPR/Cas9-KO cell line models to venetoclax or the MDM2 antagonist idasanutlin.

OCI-AML2 parental cells or cells with CRISPR-mediated knockout (KO) of the indicated three genes identified from resistance screens of Ven+Ruxolitinib were treated in vitro with either venetoclax or the MDM2 inhibitor idasanutlin (upper and lower panels, respectively). Data were normalized to untreated controls and displayed as percent viability values, then fit to non-linear regression curves.